## Riccardo C Bonadonna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7089532/publications.pdf

Version: 2024-02-01

129 papers 9,003 citations

38 h-index 93 g-index

140 all docs

140 docs citations

140 times ranked 9366 citing authors

#	Article	IF	Citations
1	Insulin Resistance in Essential Hypertension. New England Journal of Medicine, 1987, 317, 350-357.	27.0	2,338
2	HOMA-Estimated Insulin Resistance Is an Independent Predictor of Cardiovascular Disease in Type 2 Diabetic Subjects. Diabetes Care, 2002, 25, 1135-1141.	8.6	493
3	Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet, The, 2003, 362, 951-957.	13.7	441
4	Insulin Causes Endothelial Dysfunction in Humans. Circulation, 2002, 105, 576-582.	1.6	367
5	Obesity and insulin resistance in humans: A dose-response study. Metabolism: Clinical and Experimental, 1990, 39, 452-459.	3.4	333
6	The Role of Free Fatty Acid Metabolism in the Pathogenesis of Insulin Resistance in Obesity and Noninsulin-Dependent Diabetes Mellitus*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 96-107.	3 <b>.</b> 6	304
7	Carotid Atherosclerosis and Coronary Heart Disease in the Metabolic Syndrome. Diabetes Care, 2003, 26, 1251-1257.	8.6	286
8	Insulin Resistance as Estimated by Homeostasis Model Assessment Predicts Incident Symptomatic Cardiovascular Disease in Caucasian Subjects From the General Population. Diabetes Care, 2007, 30, 318-324.	8.6	283
9	Population-Based Incidence Rates and Risk Factors for Type 2 Diabetes in White Individuals: The Bruneck Study. Diabetes, 2004, 53, 1782-1789.	0.6	250
10	Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metabolism: Clinical and Experimental, 1987, 36, 502-506.	3.4	241
11	Role of Reduced β-Cell Mass Versus Impaired β-Cell Function in the Pathogenesis of Type 2 Diabetes. Diabetes Care, 2013, 36, S113-S119.	8.6	201
12	Metabolic Effects of Aerobic Training and Resistance Training in Type 2 Diabetic Subjects. Diabetes Care, 2012, 35, 676-682.	8.6	177
13	Cigarette Smoking and Insulin Resistance in Patients with Noninsulin-Dependent Diabetes Mellitus <sup>1</sup> . Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3619-3624.	3.6	154
14	Î <sup>2</sup> -Cell Function Across the Spectrum of Glucose Tolerance in Obese Youth. Diabetes, 2005, 54, 1735-1743.	0.6	149
15	Role of Tissue-Specific Blood Flow and Tissue Recruitment in Insulin-Mediated Glucose Uptake of Human Skeletal Muscle. Circulation, 1998, 98, 234-241.	1.6	145
16	Evidence for Early Defects in Insulin Sensitivity and Secretion Before the Onset of Glucose Dysregulation in Obese Youths. Diabetes, 2012, 61, 606-614.	0.6	128
17	Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5028-5036.	3.6	126
18	Metabolic Abnormalities Underlying the Different Prediabetic Phenotypes in Obese Adolescents. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1767-1773.	3.6	103

#	Article	IF	CITATIONS
19	Loss of ZnT8 function protects against diabetes by enhanced insulin secretion. Nature Genetics, 2019, 51, 1596-1606.	21.4	96
20	Very-low-calorie diet: a quick therapeutic tool to improve $\hat{l}^2$ cell function in morbidly obese patients with type 2 diabetes. American Journal of Clinical Nutrition, 2012, 95, 609-613.	4.7	93
21	Elevated 1-Hour Postload Plasma Glucose Levels Identify Subjects With Normal Glucose Tolerance but Impaired β-Cell Function, Insulin Resistance, and Worse Cardiovascular Risk Profile: The GENFIEV Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2100-2105.	3.6	92
22	Pleiotropic Effects of GIP on Islet Function Involve Osteopontin. Diabetes, 2011, 60, 2424-2433.	0.6	83
23	Insulin Sensitivity Is Correlated with Subcutaneous but Not Visceral Body Fat in Overweight and Obese Prepubertal Children. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2122-2128.	3.6	76
24	Muscle glucose transport and phosphorylation in type 2 diabetic, obese nondiabetic, and genetically predisposed individuals. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E92-E100.	3.5	72
25	Altered Homeostatic Adaptation of First- and Second-Phase Â-Cell Secretion in the Offspring of Patients With Type 2 Diabetes: Studies With a Minimal Model to Assess Â-Cell Function. Diabetes, 2003, 52, 470-480.	0.6	71
26	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. European Heart Journal Supplements, 2016, 18, C2-C12.	0.1	71
27	Transcriptomic Analysis of Human Polarized Macrophages: More than One Role of Alternative Activation?. PLoS ONE, 2015, 10, e0119751.	2.5	70
28	Effects of Liraglutide on Weight Loss, Fat Distribution, and $\hat{I}^2$ -Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. Diabetes Care, 2017, 40, 1556-1564.	8.6	69
29	Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 624-631.	2.6	67
30	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapy. Atherosclerosis Supplements, 2015, 19, 1-12.	1.2	66
31	In vivo imaging of beta cells with radiotracers: state of the art, prospects and recommendations for development and use. Diabetologia, 2016, 59, 1340-1349.	6.3	65
32	Fat Cell Size, Insulin Sensitivity, and Inflammation in Obese Children. Journal of Pediatrics, 2007, 151, 647-652.	1.8	63
33	Contribution of $\hat{l}^2$ -cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease. Journal of Hepatology, 2015, 63, 1484-1490.	3.7	61
34	Prevalence of Cardiovascular Autonomic Neuropathy in a Cohort of Patients With Newly Diagnosed Type 2 Diabetes: The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS). Diabetes Care, 2015, 38, 1487-1493.	8.6	55
35	Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study. International Journal of Molecular Sciences, 2017, 18, 1498.	4.1	49
36	High-Normal HbA1c Is a Strong Predictor of Type 2 Diabetes in the General Population. Diabetes Care, 2011, 34, 1038-1040.	8.6	47

#	Article	IF	CITATIONS
37	Protein Metabolism in Human Obesity: Relationship with Glucose and Lipid Metabolism and with Visceral Adipose Tissue $<$ sup $>$ 1 $<$ /sup $>$ . Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2552-2558.	3.6	46
38	Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events. Cardiovascular Diabetology, 2020, 19, 46.	6.8	43
39	Ghrelin, insulin sensitivity and postprandial glucose disposal in overweight and obese children. European Journal of Endocrinology, 2006, 154, 61-68.	3.7	39
40	Effects on Nitric Oxide Production of Urolithins, Gut-Derived Ellagitannin Metabolites, in Human Aortic Endothelial Cells. Molecules, 2016, 21, 1009.	3.8	37
41	Pathogenetic Mechanisms and Cardiovascular Risk. Diabetes Care, 2012, 35, 2607-2612.	8.6	36
42	Quantification of epicardial fat with cardiac CT angiography and association with cardiovascular risk factors in symptomatic patients: from the ALTER-BIO (Alternative Cardiovascular Bio-Imaging) Tj ETQqO 0 0	rgB <b>II.</b> \$Ove	rlocks10 Tf 50
43	Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology, 2017, 16, 27.	6.8	35
44	Chronic complications in patients with newly diagnosed type 2 diabetes: prevalence and related metabolic and clinical features: the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 9. BMJ Open Diabetes Research and Care, 2020, 8, e001549.	2.8	35
45	Variants of GCKR Affect Both Â-Cell and Kidney Function in Patients With Newly Diagnosed Type 2 Diabetes: The Verona Newly Diagnosed Type 2 Diabetes Study 2. Diabetes Care, 2011, 34, 1205-1210.	8.6	30
46	Estimation of blood flow heterogeneity distribution in human skeletal muscle from positron emission tomography data. Annals of Biomedical Engineering, 1997, 25, 906-910.	2.5	29
47	Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. Journal of Diabetes and Its Complications, 2014, 28, 40-44.	2.3	28
48	Vitamin D affects insulin sensitivity and $\hat{l}^2$ -cell function in obese non-diabetic youths. European Journal of Endocrinology, 2019, 181, 439-450.	3.7	27
49	Alterations of Glucose Metabolism in Type 2 Diabetes Mellitus. An Overview. Reviews in Endocrine and Metabolic Disorders, 2004, 5, 89-97.	5.7	24
50	CACNA1E Variants Affect Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes. The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 3. PLoS ONE, 2012, 7, e32755.	2.5	24
51	Consistent findings in glycaemic control, body weight and hypoglycaemia with <scp>iGlarLixi</scp> (insulin glargine/lixisenatide titratable fixedâ€ratio combination) vs insulin glargine across baseline <scp>HbA1c</scp> , <scp>BMI</scp> and diabetes duration categories in the <scp>LixiLanâ€L</scp> trial. Diabetes. Obesity and Metabolism. 2017. 19. 1408-1415.	4.4	23
52	Bioavailability of Bergamot (Citrus bergamia) Flavanones and Biological Activity of Their Circulating Metabolites in Human Pro-Angiogenic Cells. Nutrients, 2017, 9, 1328.	4.1	23
53	Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?. Acta Diabetologica, 2009, 46, 173-181.	2.5	22
54	$\hat{I}^2$ -Cell Lipotoxicity in Response to Free Fatty Acid Elevation in Prepubertal Youth. Diabetes, 2013, 62, 2917-2922.	0.6	22

#	Article	IF	Citations
55	ACE Genotype and Endothelium-Dependent Vasodilation of Conduit Arteries and Forearm Microcirculation in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1313-1319.	2.4	20
56	Effects of TiO2 and Co3O4 Nanoparticles on Circulating Angiogenic Cells. PLoS ONE, 2015, 10, e0119310.	2.5	20
57	Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of shortâ€acting and other glucagonâ€like peptideâ€1 receptor agonists. Diabetes/Metabolism Research and Reviews, 2016, 32, 497-511.	4.0	19
58	Stearic acid at physiologic concentrations induces inÂvitro lipotoxicity in circulating angiogenic cells. Atherosclerosis, 2017, 265, 162-171.	0.8	19
59	Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss. Nutrients, 2018, 10, 1872.	4.1	19
60	Î <sup>2</sup> -Cell Lipotoxicity After an Overnight Intravenous Lipid Challenge and Free Fatty Acid Elevation in African American Versus American White Overweight/Obese Adolescents. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2062-2069.	3.6	18
61	Telomere length is independently associated with subclinical atherosclerosis in subjects with type 2 diabetes: a cross-sectional study. Acta Diabetologica, 2016, 53, 661-667.	2.5	18
62	Ethnic differences in insulin secretory function between black African and white European men with early type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 1678-1687.	4.4	18
63	Claimed Effects, Outcome Variables and Methods of Measurement for Health Claims Proposed Under European Community Regulation 1924/2006 in the Framework of Maintenance of Skin Function. Nutrients, 2018, 10, 7.	4.1	18
64	Central role of the $\hat{I}^2$ -cell in driving regression of diabetes after liver transplantation in cirrhotic patients. Journal of Hepatology, 2019, 70, 954-962.	3.7	17
65	Similar effectiveness of dapagliflozin and GLPâ€1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study. Diabetes, Obesity and Metabolism, 2019, 21, 1886-1894.	4.4	17
66	Switching to insulin glargine 300 $\text{U/mL}$ : Is duration of prior basal insulin therapy important?. Diabetes Research and Clinical Practice, 2018, 142, 19-25.	2.8	16
67	Ethnic differences in intrahepatic lipid and its association with hepatic insulin sensitivity and insulin clearance between men of black and white ethnicity with early type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 2163-2168.	4.4	16
68	Glucose Tolerance Stages in Cystic Fibrosis Are Identified by a Unique Pattern of Defects of Beta-Cell Function. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1793-1802.	3.6	16
69	Pasta Structure Affects Mastication, Bolus Properties, and Postprandial Glucose and Insulin Metabolism in Healthy Adults. Journal of Nutrition, 2022, 152, 994-1005.	2.9	16
70	4 In vivo glucose transport in human skeletal muscle: tools, problems and perspectives. Bailliere's Clinical Endocrinology and Metabolism, 1993, 7, 929-960.	1.0	15
71	Absorption, Pharmacokinetics, and Urinary Excretion of Pyridines After Consumption of Coffee and Cocoaâ€Based Products Containing Coffee in a Repeated Dose, Crossover Human Intervention Study. Molecular Nutrition and Food Research, 2020, 64, e2000489.	3.3	15
72	Estimation of Blood Flow Heterogeneity in Human Skeletal Muscle Using Intravascular Tracer Data: Importance for Modeling Transcapillary Exchange. Annals of Biomedical Engineering, 1998, 26, 764-774.	2.5	14

#	Article	IF	CITATIONS
73	Lixisenatide as addâ€on treatment among patients with different βâ€eell function levels as assessed by HOMAâ€Î² index. Diabetes/Metabolism Research and Reviews, 2017, 33, e2897.	4.0	13
74	Claimed effects, outcome variables and methods of measurement for health claims on foods proposed under European Community Regulation 1924/2006 in the area of appetite ratings and weight management. International Journal of Food Sciences and Nutrition, 2018, 69, 389-409.	2.8	13
75	Associations Between Pancreatic Lipids and $\langle i \rangle \hat{l}^2 \langle j \rangle$ -Cell Function in Black African and White European Men With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1201-1210.	3.6	13
76	Insulin clearance as the major player in the hyperinsulinaemia of black African men without diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1808-1817.	4.4	13
77	Ethnic differences in beta cell function occur independently of insulin sensitivity and pancreatic fat in black and white men. BMJ Open Diabetes Research and Care, 2021, 9, e002034.	2.8	13
78	Effect of prolonged overnight fasting on energy metabolism in non-insulin-dependent diabetic and non-diabetic subjects. European Journal of Endocrinology, 1990, 123, 30-36.	3.7	12
79	Association of a 62 Variants Type 2 Diabetes Genetic Risk Score With Markers of Subclinical Atherosclerosis. Circulation: Cardiovascular Genetics, 2015, 8, 507-515.	5.1	12
80	Dysfunctional eating in type 2 diabetes mellitus: A multicenter Italian study of socio-demographic and clinical associations. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 983-990.	2.6	12
81	Effect of coffee and cocoa-based confectionery containing coffee on markers of cardiometabolic health: results from the pocket-4-life project. European Journal of Nutrition, 2021, 60, 1453-1463.	3.9	12
82	Effect of different patterns of consumption of coffee and a cocoa-based product containing coffee on the nutrikinetics and urinary excretion of phenolic compounds. American Journal of Clinical Nutrition, 2021, 114, 2107-2118.	4.7	12
83	Identification of an early transcriptomic signature of insulin resistance and related diseases in lymphomonocytes of healthy subjects. PLoS ONE, 2017, 12, e0182559.	2.5	11
84	Comparable efficacy with similarly low risk of hypoglycaemia in patient―vs physicianâ€managed basal insulin initiation and titration in insulinâ€naà ve type 2 diabetic subjects: The Italian Titration Approach Study. Diabetes/Metabolism Research and Reviews, 2020, 36, e3304.	4.0	11
85	Metabolomic Changes after Coffee Consumption: New Paths on the Block. Molecular Nutrition and Food Research, 2021, 65, 2000875.	3.3	11
86	Estimation of Organ Transport Function from Recirculating Indicator Dilution Curves. Annals of Biomedical Engineering, 1998, 26, 128-137.	2.5	10
87	Intracellular Partition of Plasma Glucose Disposal in Hypertensive and Normotensive Subjects with Type 2 Diabetes Mellitus1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2073-2079.	3.6	10
88	A Novel Insulin/Glucose Model after a Mixed-Meal Test in Patients with Type 1 Diabetes on Insulin Pump Therapy. Scientific Reports, 2016, 6, 36029.	3.3	10
89	SARS-CoV-2 Spike protein is not pro-inflammatory in human primary macrophages: endotoxin contamination and lack of protein glycosylation as possible confounders. Cell Biology and Toxicology, 2022, 38, 667-678.	5.3	10
90	Early impairment of $\hat{l}^2$ -cell function and insulin sensitivity characterizes normotolerant Caucasian women with previous gestational diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2006, 16, 485-493.	2.6	9

#	Article	IF	Citations
91	Prevalence of orthorexic traits in type 2 diabetes mellitus: at the crossroads between nutritional counseling and eating disorders. Acta Diabetologica, 2020, 57, 1117-1119.	2.5	9
92	Impact of lowering the criterion for impaired fasting glucose on identification of individuals with insulin resistance. The GISIR database Diabetes/Metabolism Research and Reviews, 2008, 24, 130-136.	4.0	7
93	Claimed effects, outcome variables and methods of measurement for health claims on foods proposed under Regulation (EC) 1924/2006 in the area of oral health. NFS Journal, 2018, 10, 10-25.	4.3	7
94	Italian Titration Approach Study (ITAS) with insulin glargine 300ÂU/mL in insulin-naÃ-ve type 2 diabetes: Design and population. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 496-503.	2.6	7
95	Rationale and methodology for a European pooled analysis of postmarketing interventional and observational studies of insulin glargine 300 U/mL in diabetes: protocol of REALI project. BMJ Open, 2020, 10, e033659.	1.9	7
96	Is common genetic variation at IRS1, ENPP1 and TRIB3 loci associated with cardiometabolic phenotypes in type 2 diabetes? An exploratory analysis of the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 5. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 232-238.	2.6	6
97	Claimed effects, outcome variables and methods of measurement for health claims on foods related to the gastrointestinal tract proposed under regulation (EC) 1924/2006. International Journal of Food Sciences and Nutrition, 2018, 69, 771-804.	2.8	6
98	Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patientâ€level pooled analysis of EDITION 1, 2 and 3. Diabetes, Obesity and Metabolism, 2019, 21, 715-719.	4.4	6
99	Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [68Ga]Ga-NODAGA-Exendin-4 Produced by a Fully Automated Method. Molecules, 2022, 27, 543.	3.8	6
100	A renal genetic risk score (GRS) is associated with kidney dysfunction in people with type 2 diabetes. Diabetes Research and Clinical Practice, 2018, 144, 137-143.	2.8	5
101	"IGT-like―status in normoglucose tolerant obese children and adolescents: the additive role of glucose profile morphology and 2-hours glucose concentration during the oral glucose tolerance test. International Journal of Obesity, 2019, 43, 1363-1369.	3.4	5
102	Impact of Age on the Effectiveness and Safety of Insulin Glargine 300 U/mL: Results from the REALI European Pooled Data Analysis. Diabetes Therapy, 2021, 12, 1073-1097.	2.5	5
103	Effect of Coffee and Cocoa-Based Confectionery Containing Coffee on Markers of DNA Damage and Lipid Peroxidation Products: Results from a Human Intervention Study. Nutrients, 2021, 13, 2399.	4.1	5
104	Interleukin-6 as a potential positive modulator of human beta-cell function: an exploratory analysisâ€"the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 6. Acta Diabetologica, 2016, 53, 393-402.	2.5	4
105	Claimed effects, outcome variables and methods of measurement for health claims proposed under Regulation (EC) 1924/2006 in the framework of bone health. PharmaNutrition, 2018, 6, 17-36.	1.7	4
106	Glycaemic Control with Insulin Glargine 300ÂU/mL in Individuals with TypeÂ2 Diabetes and Chronic Kidney Disease: A REALI European Pooled Data Analysis. Diabetes Therapy, 2021, 12, 1159-1174.	2.5	4
107	MG53 marks poor beta cell performance and predicts onset of type 2 diabetes in subjects with different degrees of glucose tolerance Diabetes and Metabolism, 2022, 48, 101292.	2.9	4
108	The $\hat{l}^2$ -cell burden index of food: A proposal. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 872-878.	2.6	3

#	Article	IF	Citations
109	Islet Volume and Indexes of β-Cell Function in Humans. Cell Transplantation, 2016, 25, 491-501.	2.5	3
110	Glomerular filtration rate decline in T2DM following diagnosis. The Verona newly diagnosed diabetes study-12. Diabetes Research and Clinical Practice, 2021, 175, 108778.	2.8	3
111	Does Gender Influence the Effectiveness and Safety of Insulin Glargine 300 U/ml in Patients with Uncontrolled Type 2 Diabetes? Results from the REALI European Pooled Analysis. Diabetes Therapy, 2021,	2.5	3
112	Impact of Reference Category and Number of Traits in the Cluster on Risk of Coronary Heart Disease in Metabolic Syndrome: Prospective Data from the Bruneck Study. Metabolic Syndrome and Related Disorders, 2011, 9, 313-318.	1.3	2
113	Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the area of blood glucose and insulin concentrations. Acta Diabetologica, 2018, 55, 391-404.	2.5	2
114	A performance score of the quality of inpatient diabetes care is a marker of clinical outcomes and suggests a causeâ€effect relationship between hypoglycaemia and the risk of inâ€hospital mortality. Diabetes/Metabolism Research and Reviews, 2020, 36, e3347.	4.0	2
115	Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an <scp>ITAS</scp> post hoc analysis. Diabetes, Obesity and Metabolism, 2022, 24, 327-331.	4.4	2
116	Methods to Assess In Vivo Insulin Sensitivity and Insulin Secretion. Endocrinology, 2018, , 317-367.	0.1	2
117	Role of monogenic diabetes genes on beta cell function in Italian patients with newly diagnosed type 2 diabetes. The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 13. Diabetes and Metabolism, 2022, 48, 101323.	2.9	2
118	Insulin resistance and beta $\hat{a} \in ell$ dysfunction in newly diagnosed type 2 diabetes: Expression, aggregation and predominance. <i>Verona Newly Diagnosed Type 2 Diabetes Study <math>10 &lt; i</math>. Diabetes/Metabolism Research and Reviews, 2022, 38, .</i>	4.0	2
119	Prevalence, ancillary clinical features and cardiovascular disease in the metabolic syndrome: the Bruneck study. International Congress Series, 2003, 1253, 13-17.	0.2	1
120	GP/EFSA/NUTRI/2014/01 Scientific substantiation of health claims made on food: collection, collation and critical analysis of information in relation to claimed effects, outcome variables and methods of measurement. EFSA Supporting Publications, 2018, 15, 1272E.	0.7	1
121	Common Variants Associated to Type 2 Diabetes in the Italian Population. Open Journal of Endocrine and Metabolic Diseases, 2021, 11, 24-42.	0.2	1
122	Exploring the determinants of ethnic differences in insulin clearance between men of Black African and White European ethnicity. Acta Diabetologica, 2021, , $1$ .	2.5	1
123	Empagliflozin does not reverse lipotoxicity-induced impairment in human myeloid angiogenic cell bioenergetics. Cardiovascular Diabetology, 2022, 21, 27.	6.8	1
124	Vascular effects of insulin. A clinical physiologist's viewpoint. International Congress Series, 2003, 1253, 191-195.	0.2	0
125	Methods to Assess In Vivo Insulin Sensitivity and Insulin Secretion. Endocrinology, 2018, , 1-51.	0.1	O
126	Claimed Effects, Outcome Variables and Methods of Measurement for Health Claims on Foods Related to Vision Proposed Under Regulation (EC) 1924/2006. Nutrients, 2018, 10, 211.	4.1	0

#	Article	IF	CITATIONS
127	Changes induced by metabolic surgery on the main components of glucose/insulin system in patients with diabetes and obesity. Acta Diabetologica, 2021, 58, 513-516.	2.5	О
128	Similar glycaemic control and risk of hypoglycaemia with patient-versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS. Acta Diabetologica, 2021, 58, 789-796.	2.5	0
129	Identification of complex models of type 2 diabetes from IVGTT data by model-based design of experiments. Computer Aided Chemical Engineering, 2013, 32, 133-138.	0.5	0